Cases & Deals

  • Home
  • Practices
  • Strides Arcolab completes $1.6 billion sale of subsidiary to Mylan

Share

Strides Arcolab completes $1.6 billion sale of subsidiary to Mylan

December 2013

Client(s) Strides Arcolab Limited

Jones Day advised India-based pharmaceutical company Strides Arcolab Limited ("Strides") on the antitrust aspects of the sale to Mylan Inc. of its Agila Specialties Global Pte. Ltd. ("Agila") subsidiary for $1.6 billion in cash. The deal was announced in a company press release on February 28, 2013.

Headquartered in Bangalore, India, Agila is a developer, manufacturer, and marketer of high-quality generic injectable products. Agila had the highest number of FDA approved generic injectables from 2008 to 2010. The deal is expected to expand Mylan’s global footprint and increase its injectable portfolio to approximately 700 drugs.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.